Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,004 matching trials from the live ClinicalTrials.gov search.
Conditions
Antibiotic Prophylaxis
Interventions
cefazolin or vancomycin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 4 Interventional

Ocular Rosacea Biome Study

NCT05296837
Conditions
Ocular Rosacea, Antimicrobial Resistance
Interventions
Doxycycline 40 MG ( 20mg twice daily), Doxycycline 200 MG ( 100 mg twice daily), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Foot Ulcer
Interventions
Collagen ORC Antimicrobial Matrix (CAM)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2004 – 2005
U.S. locations
3
States / cities
Fort Lauderdale, Florida • South Miami, Florida • Warren, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Burn, Partial Thickness
Interventions
Collagenase Santyl, Bacitracin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
2 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
Interventions
Study Drug Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Days to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more
Not yet recruiting Not applicable Interventional

Safety Study of Microlyte DualGuard

NCT07695688
Conditions
Wound Closure, Wound Care
Interventions
Microlyte DualGuard, Allevyn Foam (Standard of Care Control)
Device
Lead sponsor
Imbed Biosciences
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana
Conditions
Bacterial Infections
Interventions
QPX7728, Placebo, QPX2014
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cypress, California
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Sodium Fusidate, Placebo
Drug
Lead sponsor
Aceragen
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
25
States / cities
Gainesville, Florida • Orlando, Florida • Pensacola, Florida + 22 more
Conditions
Cystic Fibrosis
Interventions
Biaxin ( clarithromycin)
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
6 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Enrolling by invitation No phase listed Observational

Allergy Delabeling in Antibiotic Stewardship - Evaluations

NCT06967467
Conditions
Beta Lactam Allergy in Patients With a Hematologic Malignancy
Interventions
Semi-structured interview, Survey, Ethnographic observation
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Dysbiosis
Interventions
Screening Criteria Review, Pre-Travel Questionnaire, Pre-Travel Stool Specimen Collection, Short-Term Post-Travel Questionnaire, Short-Term Post-Travel Stool Specimen Collection, Long-Term Post-Travel Questionnaire, Long-Term Post-Travel Stool Specimen Collection
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Frostbite
Interventions
Long-Acting silver dressings, Aloe Vera, Dalbavancin
Device · Other · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide, benzoyl peroxide 2.5% and adapalene 0.1% gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Conditions
Infections
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 11 more
Conditions
Infection, Arthroplasty
Interventions
Prophylactic Antibiotics, Control Antibiotics
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Treatment Utility of Postpartum Antibiotics in Chorioamnionitis

NCT01585129
Conditions
The Primary Outcome of This Study Will be the Rate of Endometritis
Interventions
Postpartum Antibiotics, No postpartum antibiotics
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
St Louis, Missouri
Conditions
Evidence of Liver Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Postoperative Wound Infection-deep, Post Operative Wound Infection
Interventions
RUT058-60, Sterile saline for irrigation
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Mobile, Alabama • La Jolla, California • Houston, Texas + 1 more
Completed Phase 1Phase 2 Interventional Results available

Targeted Microbiome Transplant in Atopic Dermatitis

NCT03151148
Conditions
Atopic Dermatitis (AD)
Interventions
TMT Lotion, Placebo Lotion
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Conditions
Acute Otitis Media, Pediatric Infectious Disease, Ear Infection
Interventions
High Intensity Intervention, Low Intensity Intervention
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
2 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Saline Nasal, Budesonide Nasal, Topical Antibacterial (Product)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions
Rapid respiratory pathogen nucleic acid amplification test
Device
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 101 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California